Insight Molecular Diagnostics PE Ratio 2014-2025 | IMDX
Current and historical p/e ratio for Insight Molecular Diagnostics (IMDX) from 2014 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Insight Molecular Diagnostics PE ratio as of August 14, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Insight Molecular Diagnostics PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-08-14 | 2.40 | 0.00 | |
| 2025-03-31 | 3.06 | $-3.53 | 0.00 |
| 2024-12-31 | 2.38 | $-4.40 | 0.00 |
| 2024-09-30 | 2.85 | $-2.47 | 0.00 |
| 2024-06-30 | 2.95 | $-2.30 | 0.00 |
| 2024-03-31 | 2.93 | $-3.01 | 0.00 |
| 2023-12-31 | 2.50 | $-1.48 | 0.00 |
| 2023-09-30 | 3.12 | $-1.48 | 0.00 |
| 2023-06-30 | 4.60 | $-2.27 | 0.00 |
| 2023-03-31 | 7.08 | $-2.60 | 0.00 |
| 2022-12-31 | 6.42 | $-5.20 | 0.00 |
| 2022-09-30 | 14.60 | $-13.00 | 0.00 |
| 2022-06-30 | 18.00 | $-14.40 | 0.00 |
| 2022-03-31 | 29.80 | $-15.40 | 0.00 |
| 2021-12-31 | 43.40 | $-14.20 | 0.00 |
| 2021-09-30 | 71.20 | $-8.20 | 0.00 |
| 2021-06-30 | 114.80 | $-7.20 | 0.00 |
| 2021-03-31 | 103.80 | $-7.60 | 0.00 |
| 2020-12-31 | 47.80 | $-9.20 | 0.00 |
| 2020-09-30 | 27.80 | $-10.40 | 0.00 |
| 2020-06-30 | 38.20 | $-10.40 | 0.00 |
| 2020-03-31 | 49.00 | $-9.60 | 0.00 |
| 2019-12-31 | 45.00 | $-8.60 | 0.00 |
| 2019-09-30 | 42.00 | $-7.80 | 0.00 |
| 2019-06-30 | 49.80 | $-7.20 | 0.00 |
| 2019-03-31 | 79.00 | $-7.60 | 0.00 |
| 2018-12-31 | 27.60 | $-8.40 | 0.00 |
| 2018-09-30 | 50.00 | $-8.80 | 0.00 |
| 2018-06-30 | 51.00 | $-11.80 | 0.00 |
| 2018-03-31 | 42.00 | $-12.00 | 0.00 |
| 2017-12-31 | 93.00 | $-12.80 | 0.00 |
| 2017-09-30 | 151.00 | $-12.40 | 0.00 |
| 2017-06-30 | 104.00 | $-10.00 | 0.00 |
| 2017-03-31 | 119.00 | $-9.40 | 0.00 |
| 2016-12-31 | 141.00 | $-8.60 | 0.00 |
| 2016-09-30 | 100.80 | $-9.20 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.070B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.621B | 58.04 |
| Tempus AI (TEM) | United States | $12.054B | 0.00 |
| Doximity (DOCS) | United States | $12.025B | 53.35 |
| Hims & Hers Health (HIMS) | United States | $10.818B | 89.50 |
| IRhythm Technologies (IRTC) | United States | $5.361B | 0.00 |
| Hinge Health (HNGE) | United States | $4.529B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.584B | 37.98 |
| Privia Health (PRVA) | United States | $2.580B | 191.09 |
| Phreesia (PHR) | United States | $1.705B | 0.00 |
| Enovis (ENOV) | United States | $1.691B | 8.94 |
| 10x Genomics (TXG) | United States | $1.671B | 0.00 |
| Azenta (AZTA) | United States | $1.471B | 64.16 |
| Schrodinger (SDGR) | United States | $1.456B | 0.00 |
| Omnicell (OMCL) | United States | $1.440B | 27.74 |
| Clover Health Investments (CLOV) | United States | $1.333B | 0.00 |
| Claritev (CTEV) | United States | $1.157B | 0.00 |
| Evolent Health (EVH) | United States | $1.053B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.666B | 0.00 |
| Veradigm (MDRX) | United States | $0.509B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.504B | 0.00 |
| Standard BioTools (LAB) | United States | $0.498B | 0.00 |
| Talkspace (TALK) | United States | $0.432B | 129.00 |
| Carlsmed (CARL) | $0.365B | 0.00 | |
| Butterfly Network (BFLY) | United States | $0.357B | 0.00 |
| TruBridge (TBRG) | United States | $0.300B | 52.66 |
| Outset Medical (OM) | United States | $0.235B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.227B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.215B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.210B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.199B | 0.00 |
| CapsoVision (CV) | United States | $0.189B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.130B | 0.00 |
| American Well (AMWL) | United States | $0.112B | 0.00 |
| CareCloud (CCLD) | United States | $0.108B | 4.90 |
| EUDA Health Holdings (EUDA) | Singapore | $0.095B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.092B | 0.00 |
| Pulmonx (LUNG) | United States | $0.063B | 0.00 |
| 111 (YI) | China | $0.054B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.051B | 0.00 |
| HeartBeam (BEAT) | United States | $0.041B | 0.00 |
| Zhongchao (ZCMD) | China | $0.025B | 0.00 |
| Precipio (PRPO) | United States | $0.022B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.019B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.013B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.007B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.005B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| PROFUSA (PFSA) | United States | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |